Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
BMJ (Clinical Research Ed.)|October 13, 2011
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) StudyMargaret May, Mark Gompels, Valerie Delpech, et al.
Plos One|January 7, 2011
Rising population cost for treating people living with HIV in the UK, 1997-2013Sundhiya Mandalia, Roshni Mandalia, Gary Lo, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
Clinical Medicine (London, England)|November 5, 2009
Testing for HIV: concise guidanceAdrian Palfreeman, Martin Fisher, Ed Ong, et al.
Plos Medicine|March 27, 2012
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, Jim Young, Mina Psichogiou, et al.
AIDS (London, England)|January 16, 2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi, Andrew A Benzie, Andrew N Phillips, et al.
Plos One|January 24, 2013
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)Ann K Sullivan, Dorthe Raben, Joanne Reekie, et al.
Antiviral Therapy|September 9, 2011
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber, Anna Maria Geretti, Jane Anderson, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Clinical and Vaccine Immunology : CVI|January 25, 2013
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adultsPeter Hayes, Jill Gilmour, Andrea von Lieven, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
BMJ (Clinical Research Ed.)|October 13, 2011
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) StudyMargaret May, Mark Gompels, Valerie Delpech, et al.
Plos One|January 7, 2011
Rising population cost for treating people living with HIV in the UK, 1997-2013Sundhiya Mandalia, Roshni Mandalia, Gary Lo, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
Clinical Medicine (London, England)|November 5, 2009
Testing for HIV: concise guidanceAdrian Palfreeman, Martin Fisher, Ed Ong, et al.
Plos Medicine|March 27, 2012
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, Jim Young, Mina Psichogiou, et al.
AIDS (London, England)|January 16, 2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi, Andrew A Benzie, Andrew N Phillips, et al.
Plos One|January 24, 2013
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)Ann K Sullivan, Dorthe Raben, Joanne Reekie, et al.
Antiviral Therapy|September 9, 2011
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber, Anna Maria Geretti, Jane Anderson, et al.
Pageof 21